Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Hoffmann-La Roche
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center